← Latest news 
Cipla gets USFDA nod for generic albuterol inhalation aerosol for respiratory relief
Business
Published on 24 April 2026
Final approval could expand access to a major asthma drug
Cipla has received final approval from the USFDA for its generic albuterol sulfate inhalation aerosol, a key medicine used for respiratory conditions. The clearance strengthens Cipla’s US portfolio and provides a therapeutic equivalent to a widely used branded drug, underlining its momentum in the respiratory segment.
- USFDA grants final approval to Cipla’s generic albuterol aerosol
- The product targets respiratory relief and is a therapeutic equivalent
- Approval boosts Cipla’s portfolio in the US respiratory market
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times